VIENNA—For women with premenopausal breast cancer the benefits of using the most adjuvant endocrine treatment needs to be weighed against additional side effects—according to Marco Colleoni MD from the European Institute of Oncology in Milan. After his talk at the St Gallen breast cancer conference he discussed criteria for individualizing optimal endocrine adjuvant treatments with Oncology Times reporter Sarah Maxwell.
Endocrine Therapy in Premenopausal Breast Cancer: Most Effective Not Always Best
Further reading
The microbiome is emerging as a powerful ally to cancer doctors to harness in tandem with curative therapies, especially with allogeneic stem cell...
Bi-specific T-cell engager promise in B-cell acute lymphoblastic leukemia
Single cell transcriptome analysis yields details of molecular features that promise to help customise therapy for each individual patient.
Audio Journal of Oncology September 9, 2022 By Peter M Goodwin PARIS, France—Particulate air pollution was identified as a key step in malignant...
Babies Use Object Permanence To Get What They Want 2022: A report from the journal: Pediatric Physical Therapy Regina Harbourne PhD, PT, PCS, FAPTA...
Mandeep Mehra talks about his report in the New England Journal of Medicine on the inflammatory effects of COVID-19 infection and the implications...